Trial Profile
A randomised, double blind placebo controlled study assessing the effect of recombinant human growth hormone (r-hGH) on live birth rates in women who are poor responders undergoing an Invitro Fertilisation(IVF) or Intracytoplasmic Sperm Injection(ICSI) cycle
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Recombinant follicle-stimulating hormone (Primary)
- Indications Infertility
- Focus Therapeutic Use
- Acronyms LIGHT
- 08 Jun 2016 Status changed from recruiting to completed.
- 12 Jul 2012 Actual initiation date (15 Dec 2009) added as reported by Australian New Zealand Clinical Trials Registry record.
- 12 Jul 2012 Additional lead trial centre (Genea) added as reported by Australian New Zealand Clinical Trials Registry record.